Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD
NCT05499130Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 2 trial of duvakitug in ulcerative colitis (UC), Crohn's disease, sponsored by Teva Pharmaceutical Industries Ltd.. Started Sep 2022; status: completed.
02
Drugs
duvakitug
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05499130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05499130.